Genentech and OSI Pharmaceuticals will be paying $67 million to resolve claims they made misleading statements about the effectiveness of lung cancer drug Tarceva, according to the U.S. Justice Department, as reported in a Reuters article.
The claims alleged that between 2006 and 2011, the companies misrepresented the drug to doctors and healthcare providers to treat patients with non-small cell lung cancer, the department said.
As a part of the settlement, the federal government will get $62.6 million and state Medicaid programs will get $4.4 million.
Read the Reuters story